Ductal breast carcinoma in situ

Summary

Ductal breast carcinoma in situ (MONDO:0005023) is a cancer with 1 cohort gene (1 CIViC-evidence somatic driver; 1 ClinVar predisposition record) and 159 clinical trials. Top therapeutic interventions include lapatinib, oxybutynin, and tamoxifen.

At a glance

• Classification: Cancer
• Cohort genes: 1
• ClinVar variants: 1
• Clinical trials: 159

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ductal breast carcinoma in situ
Mondo ID	MONDO:0005023
EFO	EFO:0000432
MeSH	D002285
DOID	DOID:0060074
NCIT	C2924
UMLS	C0007124
MedGen	765
Anatomy (UBERON)	UBERON:0001765
Is cancer (heuristic)	yes

Also known as: breast ductal carcinoma in situ · carcinoma in situ of mammary duct · DCIS · ductal breast carcinoma in situ · ductal carcinoma in situ · ductal carcinoma in situ (DCIS) · ductal carcinoma in situ of breast · ductal carcinoma in situ of the breast · intraductal breast carcinoma · intraductal carcinoma · intraductal carcinoma of breast · intraductal carcinoma of the breast · mammary duct carcinoma in situ · mammary duct in situ carcinoma · non-infiltrating ductal adenocarcinoma of breast · non-infiltrating ductal adenocarcinoma of the breast · non-infiltrating ductal breast adenocarcinoma · non-infiltrating ductal breast carcinoma · non-infiltrating ductal carcinoma of breast · non-infiltrating ductal carcinoma of the breast (+15 more)

Data availability: 1 ClinVar variant.

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › in situ carcinoma › adenocarcinoma in situ › ductal breast carcinoma in situ

Related subtypes (2): lung adenocarcinoma in situ, lobular breast carcinoma in situ

Subtypes (1): intraductal cribriform breast adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
12356	NM_000546.6(TP53):c.743G>A (p.Arg248Gln)	TP53	Pathogenic	reviewed by expert panel

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 20 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
TP53	LoF	ACC,ALL,AML,ANGS,ANSC,BCC,BL,BLADDER,BLCA,BRCA,CCRCC,CEAD,CESC,CHOL,CHRCC,CLLSLL,COAD,COADREAD,CSCC,DLBCLNOS,EGC,ES,ESCA,ESCC,GB,GBC,GBM,GIST,HCC,HGGNOS,HNSC,LGGNOS,LIPO,LMS,LNM,LUAD,LUSC,MBL,MEL,MLYM,MT,NBL,NETNOS,NHL,NPC,NSCLC,OS,OVT,PAAD,PANCREAS,PAST,PCM,PLMESO,PRAD,PRCC,PROSTATE,RCC,READ,SACA,SARCNOS,SCLC,SIC,SKCM,SKIN,SOFT_TISSUE,STAD,STOMACH,THYM,UCEC,UCS,UTUC,VULVA,WDTC,WT	CIViC #45

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
TP53	Orphanet:1333	Familial pancreatic carcinoma
TP53	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
TP53	Orphanet:1501	Adrenocortical carcinoma
TP53	Orphanet:210159	Adult hepatocellular carcinoma
TP53	Orphanet:251576	Gliosarcoma
TP53	Orphanet:251579	Giant cell glioblastoma
TP53	Orphanet:251899	Choroid plexus carcinoma
TP53	Orphanet:2807	Papilloma of choroid plexus
TP53	Orphanet:293199	Pleomorphic rhabdomyosarcoma
TP53	Orphanet:3318	Essential thrombocythemia
TP53	Orphanet:524	Li-Fraumeni syndrome
TP53	Orphanet:52688	Myelodysplastic syndrome
TP53	Orphanet:585909	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
TP53	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
TP53	Orphanet:668	Osteosarcoma
TP53	Orphanet:67038	B-cell chronic lymphocytic leukemia
TP53	Orphanet:70573	Small cell lung cancer
TP53	Orphanet:96253	Cushing disease
TP53	Orphanet:99756	Alveolar rhabdomyosarcoma
TP53	Orphanet:99757	Embryonal rhabdomyosarcoma

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
TP53	HGNC:11998	ENSG00000141510	P04637	Cellular tumor antigen p53	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
TP53	Cellular tumor antigen p53	Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Transcription factor	1	8.3×	0.121

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
TP53	Transcription factor	no		p53_tumour_suppressor, p53-like_TF_DNA-bd_sf, p53_tetrameristn

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
ganglionic eminence	1
tendon of biceps brachii	1
ventricular zone	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
TP53	223	ubiquitous	marker	ventricular zone, ganglionic eminence, tendon of biceps brachii

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
TP53	22,736

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
TP53	P04637	313

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 46. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Loss of function of TP53 in cancer due to loss of tetramerization ability	1	11420.0×	0.004	TP53
Regulation of TP53 Expression	1	5710.0×	0.004	TP53
Transcriptional activation of cell cycle inhibitor p21	1	2855.0×	0.004	TP53
Activation of NOXA and translocation to mitochondria	1	1903.3×	0.004	TP53
RUNX3 regulates CDKN1A transcription	1	1631.4×	0.004	TP53
PI5P Regulates TP53 Acetylation	1	1268.9×	0.004	TP53
Activation of PUMA and translocation to mitochondria	1	1142.0×	0.004	TP53
TP53 Regulates Transcription of Caspase Activators and Caspases	1	951.7×	0.004	TP53
TP53 Regulates Transcription of Death Receptors and Ligands	1	951.7×	0.004	TP53
Urea cycle	1	878.5×	0.004	TP53
Regulation of TP53 Activity through Association with Co-factors	1	815.7×	0.004	TP53
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	1	761.3×	0.004	TP53
Stabilization of p53	1	761.3×	0.004	TP53
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	1	713.8×	0.004	TP53
Formation of Senescence-Associated Heterochromatin Foci (SAHF)	1	671.8×	0.004	TP53
Zygotic genome activation (ZGA)	1	671.8×	0.004	TP53
Regulation of NF-kappa B signaling	1	634.4×	0.004	TP53
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	1	601.0×	0.004	TP53
SUMOylation of transcription factors	1	571.0×	0.004	TP53
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	1	543.8×	0.004	TP53
Regulation of TP53 Activity through Methylation	1	543.8×	0.004	TP53
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain	1	519.1×	0.004	TP53
Regulation of TP53 Activity through Acetylation	1	456.8×	0.004	TP53
Pyroptosis	1	423.0×	0.005	TP53
Oncogene Induced Senescence	1	335.9×	0.005	TP53
Association of TriC/CCT with target proteins during biosynthesis	1	292.8×	0.006	TP53
Regulation of TP53 Degradation	1	292.8×	0.006	TP53
Ovarian tumor domain proteases	1	278.5×	0.006	TP53
Autodegradation of the E3 ubiquitin ligase COP1	1	265.6×	0.006	TP53
Transcriptional Regulation by VENTX	1	265.6×	0.006	TP53

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
negative regulation of helicase activity	1	16852.0×	0.002	TP53
cellular response to actinomycin D	1	16852.0×	0.002	TP53
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	1	16852.0×	0.002	TP53
negative regulation of G1 to G0 transition	1	16852.0×	0.002	TP53
positive regulation of mitochondrial membrane permeability	1	8426.0×	0.002	TP53
oligodendrocyte apoptotic process	1	8426.0×	0.002	TP53
negative regulation of glucose catabolic process to lactate via pyruvate	1	8426.0×	0.002	TP53
negative regulation of pentose-phosphate shunt	1	8426.0×	0.002	TP53
obsolete homolactic fermentation	1	5617.3×	0.002	TP53
signal transduction by p53 class mediator	1	5617.3×	0.002	TP53
negative regulation of miRNA processing	1	5617.3×	0.002	TP53
intrinsic apoptotic signaling pathway in response to hypoxia	1	5617.3×	0.002	TP53
regulation of fibroblast apoptotic process	1	5617.3×	0.002	TP53
T cell proliferation involved in immune response	1	4213.0×	0.002	TP53
positive regulation of programmed necrotic cell death	1	4213.0×	0.002	TP53
oxidative stress-induced premature senescence	1	4213.0×	0.002	TP53
B cell lineage commitment	1	3370.4×	0.002	TP53
T cell lineage commitment	1	3370.4×	0.002	TP53
mRNA transcription	1	3370.4×	0.002	TP53
positive regulation of RNA polymerase II transcription preinitiation complex assembly	1	3370.4×	0.002	TP53
positive regulation of thymocyte apoptotic process	1	3370.4×	0.002	TP53
cellular response to UV-C	1	3370.4×	0.002	TP53
regulation of mitochondrial membrane permeability involved in apoptotic process	1	2808.7×	0.002	TP53
viral process	1	2407.4×	0.002	TP53
mitochondrial DNA repair	1	2407.4×	0.002	TP53
regulation of cell cycle G2/M phase transition	1	2407.4×	0.002	TP53
regulation of tissue remodeling	1	2106.5×	0.002	TP53
regulation of DNA damage response, signal transduction by p53 class mediator	1	2106.5×	0.002	TP53
response to salt stress	1	1872.4×	0.002	TP53
circadian behavior	1	1872.4×	0.002	TP53

Therapeutics

Drugs indicated for this disease

0 approved, 5 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Anastrozole	Phase 3 (in late-stage trials)
Exemestane	Phase 3 (in late-stage trials)
Letrozole	Phase 3 (in late-stage trials)
Tamoxifen	Phase 3 (in late-stage trials)
Trastuzumab	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Afimoxifene, Bazedoxifene, Carboplatin, Doconexent, Doxorubicin, Elacestrant, Endoxifen, Epigalocatechin Gallate, Fulvestrant, Icosapent, Oxytocin, Palbociclib, Sargramostim, Sodium Chloride, Testosterone.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
TP53	NITROFURANTOIN

Top cohort targets by molecule count

Symbol	Molecules	Max phase
TP53	196	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
NITROFURANTOIN	4	TP53
DIOSMIN	4	TP53
VERTEPORFIN	4	TP53
CANDESARTAN CILEXETIL	4	TP53
DIENESTROL	4	TP53
CLOTRIMAZOLE	4	TP53
COLCHICINE	4	TP53
NABUMETONE	4	TP53
SALMETEROL XINAFOATE	4	TP53
AMIODARONE HYDROCHLORIDE	4	TP53
FURAZOLIDONE	4	TP53
AMOXAPINE	4	TP53
RALOXIFENE HYDROCHLORIDE	4	TP53
NICARDIPINE HYDROCHLORIDE	4	TP53
SULCONAZOLE NITRATE	4	TP53
PYRITHIONE ZINC	4	TP53
LACTIC ACID	4	TP53
OXYMETHOLONE	4	TP53
CHLOROXINE	4	TP53
PROPIOLACTONE	4	TP53
CLOMIPRAMINE HYDROCHLORIDE	4	TP53
PHENYL AMINOSALICYLATE	4	TP53
THIORIDAZINE HYDROCHLORIDE	4	TP53
AMITRIPTYLINE HYDROCHLORIDE	4	TP53
ETHOPROPAZINE HYDROCHLORIDE	4	TP53
MECHLORETHAMINE HYDROCHLORIDE	4	TP53
ECONAZOLE NITRATE	4	TP53
TRIFLUPROMAZINE HYDROCHLORIDE	4	TP53
PROCHLORPERAZINE EDISYLATE	4	TP53
DEQUALINIUM CHLORIDE	4	TP53

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
TP53	869	Binding:775, ADMET:83, Functional:10, Toxicity:1

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
TP53	869

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

30 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
NITROFURANTOIN	4	TP53
DIOSMIN	4	TP53
VERTEPORFIN	4	TP53
CANDESARTAN CILEXETIL	4	TP53
DIENESTROL	4	TP53
CLOTRIMAZOLE	4	TP53
COLCHICINE	4	TP53
NABUMETONE	4	TP53
SALMETEROL XINAFOATE	4	TP53
AMIODARONE HYDROCHLORIDE	4	TP53
FURAZOLIDONE	4	TP53
AMOXAPINE	4	TP53
RALOXIFENE HYDROCHLORIDE	4	TP53
NICARDIPINE HYDROCHLORIDE	4	TP53
SULCONAZOLE NITRATE	4	TP53
PYRITHIONE ZINC	4	TP53
LACTIC ACID	4	TP53
OXYMETHOLONE	4	TP53
CHLOROXINE	4	TP53
PROPIOLACTONE	4	TP53
CLOMIPRAMINE HYDROCHLORIDE	4	TP53
PHENYL AMINOSALICYLATE	4	TP53
THIORIDAZINE HYDROCHLORIDE	4	TP53
AMITRIPTYLINE HYDROCHLORIDE	4	TP53
ETHOPROPAZINE HYDROCHLORIDE	4	TP53
MECHLORETHAMINE HYDROCHLORIDE	4	TP53
ECONAZOLE NITRATE	4	TP53
TRIFLUPROMAZINE HYDROCHLORIDE	4	TP53
PROCHLORPERAZINE EDISYLATE	4	TP53
DEQUALINIUM CHLORIDE	4	TP53

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	TP53
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 159.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	87
PHASE2	44
PHASE1	9
PHASE3	7
PHASE1/PHASE2	6
EARLY_PHASE1	3
PHASE4	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00742222	PHASE4	COMPLETED	Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
NCT04248179	PHASE4	COMPLETED	The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery.
NCT01272037	PHASE3	ACTIVE_NOT_RECRUITING	Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
NCT01905046	PHASE3	ACTIVE_NOT_RECRUITING	Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
NCT04722692	PHASE3	RECRUITING	Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
NCT00757302	PHASE3	COMPLETED	Intraoperative Gamma Camera for Breast Cancer Surgery
NCT00769379	PHASE3	COMPLETED	Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
NCT02961790	PHASE3	COMPLETED	Oxybutynin Chloride in Managing Hot Flashes
NCT03077841	PHASE2/PHASE3	SUSPENDED	Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer
NCT04046159	PHASE3	UNKNOWN	Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ
NCT00165256	PHASE2	ACTIVE_NOT_RECRUITING	Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast
NCT01245712	PHASE2	ACTIVE_NOT_RECRUITING	Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
NCT01266642	PHASE2	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
NCT03936478	PHASE2	RECRUITING	Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
NCT04009044	PHASE2	ACTIVE_NOT_RECRUITING	Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
NCT04084730	PHASE2	RECRUITING	Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
NCT04666961	PHASE2	RECRUITING	Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ
NCT05023967	PHASE2	ACTIVE_NOT_RECRUITING	Metformin and Nightly Fasting in Women With Early Breast Cancer
NCT05545150	PHASE2	ACTIVE_NOT_RECRUITING	Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study
NCT05941520	PHASE2	RECRUITING	Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
NCT06033092	PHASE2	ACTIVE_NOT_RECRUITING	Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion
NCT06075953	PHASE2	RECRUITING	DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
NCT06184750	PHASE2	RECRUITING	Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
NCT06195306	PHASE2	RECRUITING	Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
NCT06538389	PHASE2	RECRUITING	High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
NCT06677944	PHASE2	RECRUITING	Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer
NCT06868238	PHASE2	RECRUITING	Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)
NCT06902311	PHASE2	RECRUITING	Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
NCT06961955	PHASE2	RECRUITING	5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
NCT00256217	PHASE2	COMPLETED	Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
NCT00586326	PHASE2	COMPLETED	MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ
NCT00669747	PHASE2	UNKNOWN	Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)
NCT00952731	PHASE2	COMPLETED	4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
NCT01023477	PHASE1/PHASE2	COMPLETED	Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
NCT01060345	PHASE2	TERMINATED	A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ
NCT01100489	PHASE2	WITHDRAWN	Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer
NCT01194440	PHASE2	COMPLETED	Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
NCT01372618	PHASE1/PHASE2	TERMINATED	Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor
NCT01754519	PHASE2	TERMINATED	Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery
NCT01849250	PHASE2	COMPLETED	Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LAPATINIB	4	4
OXYBUTYNIN	4	3
TAMOXIFEN	4	2
ABEMACICLIB	4	1
ANASTROZOLE	4	1
ATORVASTATIN	4	1
BAZEDOXIFENE	4	1
BEXAROTENE	4	1
ELACESTRANT	4	1
ESTROGENS, CONJUGATED	4	1
EXEMESTANE	4	1
FEZOLINETANT	4	1
LETROZOLE	4	1
METFORMIN	4	1
OMEGA-3-ACID ETHYL ESTERS	4	1
PASIREOTIDE	4	1
ROPIVACAINE	4	1
SINECATECHINS	4	1
SUFENTANIL	4	1
TRASTUZUMAB	4	1
AFIMOXIFENE	3	4
ENDOXIFEN	3	2
DOCONEXENT	3	1
TELAPRISTONE ACETATE	3	1
ACOLBIFENE HYDROCHLORIDE	2	1
GADOLINIUM	2	1
SOY ISOFLAVONES	2	1
UAB-30	1	1
CHEMBL2137046	0	3
CHEMBL4439413	0	1